McKesson Corporation vs Transocean Ltd — how do they compare? McKesson Corporation trades at $901.77 (market cap $102.58B), while Transocean Ltd trades at $5.79 (market cap $6.39B). The key difference: McKesson Corporation is far larger — about 16.1× Transocean Ltd's market cap, and McKesson Corporation pays a 0.43% dividend while Transocean Ltd pays none. Which is the better fit depends on your goals.
| MCK | RIG | |
|---|---|---|
Market Cap | $102.58B | $6.39B |
Sector | Health | Technology |
52-Week High | $995.69 | $7.58 |
52-Week Low | $659.01 | $2.80 |
Enterprise Value | $109.12B | $11.00B |
Dividend Yield | 0.43% | — |
Signals from Pluang's Aura AI — not financial advice
McKesson (MCK) trades at $869.58, down 0.14% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with revenue growth to $359.05B in 2025 and consistent earnings beats, including Q2 2026 EPS of $9.93 versus $9.56 expected. Valuation metrics like P/E of 23.33 and P/S of 0.26 indicate reasonable pricing relative to peers. Recent news highlights Q1 2027 results exceeding expectations and raised full-year guidance, driven by specialty drug and oncology growth.
Outlook remains positive with 80% analyst buy ratings and a $1,000 consensus price target, suggesting 15% upside. Risks include thin net margins of 1.12% and high liabilities at $76.83B, which could pressure equity during economic downturns. Investors should focus on execution of raised guidance and margin improvements from cost efficiencies.
Transocean (RIG) trades at $5.26, up 1.94% with neutral technical signals. The company shows mixed fundamentals with strong revenue growth to $4.1B in 2026 but persistent net losses improving to -$1.7B. Recent Q2 2026 earnings beat expectations with $0.03 EPS, and the company secured a significant $1B+ contract with Equinor, boosting long-term visibility. Analyst sentiment is divided with 39% buy ratings, while institutional activity shows mixed positioning with recent large acquisitions by Elliott Investment Management.
RIG presents a turnaround opportunity with improving operational metrics and contract wins, but significant execution risks remain. The pending Valaris merger could create synergies, though current negative profitability and high debt require careful monitoring. The stock offers speculative upside if operational improvements continue, but investors should weigh the substantial losses against the company's market position and backlog growth.
Trailing returns across standard periods
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →Transocean Ltd. is a leading international provider of offshore contract drilling services for oil and gas wells. The company operates one of the world's most versatile fleets of mobile offshore drilling units, including ultra-deepwater drillships and harsh environment semi-submersibles. RIG's services are essential to energy exploration and production companies seeking to access deepwater and challenging reserves globally.
Read more on RIG →